The Oncology Institute, Inc.
TOI
$3.31
$0.082.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 22.16% | 6.75% | -18.10% | -48.50% | -54,750.00% |
| Total Depreciation and Amortization | 7.05% | 12.19% | 27.58% | 29.83% | 33.14% |
| Total Amortization of Deferred Charges | 1.61% | 1.58% | 13.63% | 57.32% | 153.89% |
| Total Other Non-Cash Items | -76.87% | -57.01% | 116.13% | 901.44% | 167.02% |
| Change in Net Operating Assets | 665.54% | 226.50% | 94.92% | 125.42% | 111.48% |
| Cash from Operations | 26.92% | 25.42% | 25.23% | 38.99% | 41.20% |
| Capital Expenditure | 17.04% | 49.22% | 29.09% | 47.57% | 17.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 96.73% | 96.06% | 48.05% | 48.05% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.23% | 116.66% | 191.29% | 173.43% | 160.99% |
| Cash from Investing | -26.23% | 223.14% | 173.85% | 156.70% | 147.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 64.54% | 35.38% | 66.78% | 39.81% | 33.49% |
| Issuance of Common Stock | -40.48% | -58.68% | -61.42% | -76.81% | -85.31% |
| Repurchase of Common Stock | -- | 100.00% | 86.02% | 89.17% | 89.17% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 8.20% | -764.78% | 4.96% | 47.87% | 38.06% |
| Cash from Financing | 49.00% | 13.60% | -105.61% | -106.59% | -107.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.93% | 158.62% | 121.33% | 125.91% | 119.25% |